| 词条 | SQ109 |
| 释义 |
| Watchedfields = changed | verifiedrevid = 424997271 | ImageFile = AntitubercularSQ109.svg | ImageSize = 275px | IUPACName = N-Adamantan-2-yl-N'-((E)-3,7-dimethyl-octa-2,6-dienyl)-ethane-1,2-diamine | OtherNames = |Section1={{Chembox Identifiers | IUPHAR_ligand = 7997 | CASNo = | PubChem = 5274428 | SMILES = CC(=CCC/C(=C/CNCCN[C@@H]1C2CC3CC(C2)CC1C3)/C)C }} |Section2={{Chembox Properties | C=22 | H=38 | N=2 | MolarMass = | Appearance = | Density = | MeltingPt = | BoilingPt = | Solubility = }} |Section3={{Chembox Hazards | MainHazards = | FlashPt = | AutoignitionPt = }} }}SQ109 is a drug undergoing development for treatment of tuberculosis.[1][2] BackgroundOn October 16, 2007, it was given the status of Orphan drug by the U.S. Food and Drug Administration (FDA) for use against drug-susceptible and drug-resistant TB bacteria.[3] SQ109 completed three phase I studies in the U.S. and one Phase II efficacy studies in tuberculosis patients in Africa. SQ109 showed activity against both drug susceptible and multi-drug-resistant tuberculosis bacteria, including extensively drug-resistant tuberculosis strains. In preclinical studies SQ109 enhanced the activity of anti-tubercular drugs isoniazid and rifampin and reduced by >30% the time required to cure mice of experimental TB. SQ109 is being developed by OOO Infectex in Russia and by Sequella Inc internationally. In July 2012, Infectex received notification from the Russian Ministry of Health for approval to begin the pivotal clinical trial associated with a drug registration submission, and can proceed with the clinical development of SQ109 for treatment of tuberculosis in the Russian Federation.[4] See also
References1. ^{{Cite journal | last1 = Jia | first1 = L. | last2 = Tomaszewski | first2 = J. E. | last3 = Hanrahan | first3 = C. | last4 = Coward | first4 = L. | last5 = Noker | first5 = P. | last6 = Gorman | first6 = G. | last7 = Nikonenko | first7 = B. | last8 = Protopopova | first8 = M. | title = Pharmacodynamics and pharmacokinetics of SQ109, a new diamine-based antitubercular drug | journal = British Journal of Pharmacology | volume = 144 | issue = 1 | pages = 80–87 | year = 2009 | pmid = 15644871 | pmc = 1575972 | doi = 10.1038/sj.bjp.0705984}} {{Antimycobacterials}}{{antiinfective-drug-stub}}2. ^{{Cite journal | last1 = Meng | first1 = Q. | last2 = Luo | first2 = H. | last3 = Liu | first3 = Y. | last4 = Li | first4 = W. | last5 = Zhang | first5 = W. | last6 = Yao | first6 = Q. | title = Synthesis and evaluation of carbamate prodrugs of SQ109 as antituberculosis agents | journal = Bioorganic & Medicinal Chemistry Letters | volume = 19 | issue = 10 | pages = 2808–10 | year = 2009 | doi = 10.1016/j.bmcl.2009.03.091 | pmid=19362471}} 3. ^{{cite web |url=http://www.medscape.com/viewarticle/565674?src=mp |title=New FDA Orphan Drugs: AVI-4658, SQ109, ATIR |date=11 November 2007|work=Medscape Medical News}} 4. ^{{cite web |url=https://www.reuters.com/article/2012/07/26/idUS37877+26-Jul-2012+BW20120726 |title=PRESS RELEASE Maxwell Biotech Venture Fund`s Portfolio Company, Infectex, Receives Russian Regulator`s Approval to Conduct Pivotal Clinical Trial for Sequella's Antibiotic, SQ109, for Tuberculosis |date=26 July 2012 |publisher=Reuters}} 5 : Adamantanes|Anti-tuberculosis drugs|Russian inventions|Amines|Alkenes |
| 随便看 |
开放百科全书收录14589846条英语、德语、日语等多语种百科知识，基本涵盖了大多数领域的百科知识，是一部内容自由、开放的电子版国际百科全书。